(Q46083552)

19 December 2017

title

Cardio-renal protection with aliskiren, a direct renin inhibitor, in the ASPIRE HIGHER program (English)

1 reference

19 December 2017

author

Hae-Young Lee

series ordinal

1

1 reference

19 December 2017

Byung-Hee Oh

series ordinal

2

object named as

Byung-Hee Oh

1 reference

19 December 2017

publication date

1 March 2009

1 reference

19 December 2017

Expert Review of Cardiovascular Therapy

published in

1 reference

19 December 2017

volume

7

1 reference

19 December 2017

issue

3

1 reference

19 December 2017

page(s)

251-257

1 reference

19 December 2017

Structure-based design of aliskiren, a novel orally effective renin inhibitor

cites work

1 reference

https://api.crossref.org/works/10.1586%2F14779072.7.3.251

Aliskiren, a novel orally effective renin inhibitor, provides dose-dependent antihypertensive efficacy and placebo-like tolerability in hypertensive patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14779072.7.3.251

Renin inhibition with aliskiren provides additive antihypertensive efficacy when used in combination with hydrochlorothiazide.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14779072.7.3.251

Aliskiren, the first renin inhibitor for treating hypertension: reactive renin secretion may limit its effectiveness

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14779072.7.3.251

Clinical trials update from the European Society of Cardiology Congress 2007: 3CPO, ALOFT, PROSPECT and statins for heart failure

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14779072.7.3.251

Clinical trials update from the European Society of Cardiology Congress in Vienna, 2007: PROSPECT, EVEREST, ARISE, ALOFT, FINESSE, Prague-8, CARESS in MI and ACUITY.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14779072.7.3.251

Heart Disease and Stroke Statistics--2008 Update: A Report From the American Heart Association Statistics Committee and Stroke Statistics Subcommittee

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14779072.7.3.251

ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure 2008: the Task Force for the Diagnosis and Treatment of Acute and Chronic Heart Failure 2008 of the European Society of Cardiology

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14779072.7.3.251

ACC/AHA 2005 Guideline Update for the Diagnosis and Management of Chronic Heart Failure in the Adult: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Writing Committee to Update the [...]

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14779072.7.3.251

Effects of valsartan on circulating brain natriuretic peptide and norepinephrine in symptomatic chronic heart failure: the Valsartan Heart Failure Trial (Val-HeFT).

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14779072.7.3.251

Isosorbide dinitrate and hydralazine in a fixed-dose combination produces further regression of left ventricular remodeling in a well-treated black population with heart failure: results from A-HeFT.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14779072.7.3.251

Beneficial neurohormonal profile of spironolactone in severe congestive heart failure: results from the RALES neurohormonal substudy

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14779072.7.3.251

Aliskiren combined with losartan in type 2 diabetes and nephropathy

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14779072.7.3.251

KDOQI Clinical Practice Guidelines and Clinical Practice Recommendations for Diabetes and Chronic Kidney Disease.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14779072.7.3.251

Epidemiological data of treated end-stage renal failure in the European Union (EU) during the year 1995: report of the European Renal Association Registry and the National Registries.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14779072.7.3.251

The effect of irbesartan on the development of diabetic nephropathy in patients with type 2 diabetes

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14779072.7.3.251

Effects of losartan on renal and cardiovascular outcomes in patients with type 2 diabetes and nephropathy

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14779072.7.3.251

Renal outcomes with telmisartan, ramipril, or both, in people at high vascular risk (the ONTARGET study): a multicentre, randomised, double-blind, controlled trial.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14779072.7.3.251

Albuminuria, a therapeutic target for cardiovascular protection in type 2 diabetic patients with nephropathy

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14779072.7.3.251

Effect of the direct Renin inhibitor aliskiren, the Angiotensin receptor blocker losartan, or both on left ventricular mass in patients with hypertension and left ventricular hypertrophy

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14779072.7.3.251

Assessment of prevalence of left ventricular hypertrophy in hypertension.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14779072.7.3.251

Surrogate markers for cardiovascular disease: structural markers

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14779072.7.3.251

Regression of electrocardiographic left ventricular hypertrophy during antihypertensive treatment and the prediction of major cardiovascular events

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14779072.7.3.251

Cardiovascular morbidity and mortality in the Losartan Intervention For Endpoint reduction in hypertension study (LIFE): a randomised trial against atenolol

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14779072.7.3.251

Preventing left ventricular hypertrophy by ACE inhibition in hypertensive patients with type 2 diabetes: a prespecified analysis of the Bergamo Nephrologic Diabetes Complications Trial (BENEDICT).

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14779072.7.3.251

Reversal of left ventricular hypertrophy in essential hypertension. A meta-analysis of randomized double-blind studies

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14779072.7.3.251

Regression of hypertensive left ventricular hypertrophy by losartan compared with atenolol: the Losartan Intervention for Endpoint Reduction in Hypertension (LIFE) trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14779072.7.3.251

Angiotensin II receptor blockers and cardiovascular protection: focus on left ventricular hypertrophy regression and atrial fibrillation prevention.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14779072.7.3.251

Magnetic resonance imaging compared to echocardiography to assess left ventricular mass in the hypertensive patient.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14779072.7.3.251

Studies on left ventricular hypertrophy regression in arterial hypertension: a clear message for the clinician?

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14779072.7.3.251

Are demographic characteristics, health care access and utilization, and comorbid conditions associated with hypertension among US adults?

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14779072.7.3.251

Aliskiren, the first in a new class of direct renin inhibitors for hypertension: present and future perspectives

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14779072.7.3.251

21 January 2018

The power to TRANSCEND.

1 reference

https://api.crossref.org/works/10.1586%2F14779072.7.3.251

Renin inhibition with aliskiren: where are we now, and where are we going?

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14779072.7.3.251

Effects of renin-angiotensin system inhibition on end-organ protection: can we do better?

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14779072.7.3.251

Telmisartan, ramipril, or both in patients at high risk for vascular events

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14779072.7.3.251

2007 Guidelines for the Management of Arterial Hypertension

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14779072.7.3.251

21 January 2018

Identifiers

DOI

10.1586/14779072.7.3.251

1 reference

19 December 2017

1 reference

19 December 2017